Home Cart Sign in  
Chemical Structure| 1216941-48-8 Chemical Structure| 1216941-48-8

Structure of Paritaprevir
CAS No.: 1216941-48-8

Chemical Structure| 1216941-48-8

*Storage: {[sel_prStorage]}

*Shipping: {[sel_prShipping]}

,{[proInfo.pro_purity]}

Paritaprevir is an inhibitor of NS3-4A serine protease that may be used for treatment of hepatitis C.

Synonyms: Veruprevir; ABT-450

4.5 *For Research Use Only !

{[proInfo.pro_purity]}
Cat. No.: {[proInfo.prAm]} Purity: {[proInfo.pro_purity]}

Change View

Size Price VIP Price

US Stock

Global Stock

In Stock
{[ item.pr_size ]} Inquiry {[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate,item.pr_is_large_size_no_price, item.vip_usd) ]}

US Stock: ship in 0-1 business day
Global Stock: ship in 5-7 days

  • {[ item.pr_size ]}

In Stock

- +

Please Login or Create an Account to: See VIP prices and availability

US Stock: ship in 0-1 business day
Global Stock: ship in 2 weeks

  • 1-2 Day Shipping
  • High Quality
  • Technical Support
Product Citations

Alternative Products

Product Details of Paritaprevir

CAS No. :1216941-48-8
Formula : C40H43N7O7S
M.W : 765.88
SMILES Code : O=C([C@]1(NC([C@@]2([H])N3C[C@H](OC4=C(C=CC=C5)C5=C6C(C=CC=C6)=N4)C2)=O)[C@H](/C=C\CCCCC[C@H](NC(C7=NC=C(C)N=C7)=O)C3=O)C1)NS(=O)(C8CC8)=O
Synonyms :
Veruprevir; ABT-450
MDL No. :MFCD28411394

Safety of Paritaprevir

GHS Pictogram:
Signal Word:Warning
Hazard Statements:H302-H315-H319-H335
Precautionary Statements:P280-P305+P351+P338

Isoform Comparison

Biological Activity

In Vitro:

Cell Line
Concentration Treated Time Description References
Human pulmonary microvascular endothelial (HM) cells 0.01 µM 24 hours To evaluate the effect of Paritaprevir on LPS-induced injury in HM cells. Results showed that Paritaprevir significantly decreased nuclear β-catenin and FOX-O1 levels, increased cytoplasmic p-FOX-O1 and β-catenin levels, and significantly increased VE-cadherin, p-Akt, and claudin-5 expression. Arch Pharm Res. 2023 Jun;46(6):564-572

In Vivo:

Species
Animal Model
Administration Dosage Frequency Description References
Male SD rats LPS-induced acute lung injury (ALI) model Gavage 30 mg/kg Paritaprevir + 20 mg/kg Ritonavir 3 consecutive days To evaluate the protective effect of Paritaprevir on LPS-induced ALI. Results showed that Paritaprevir significantly reduced lung coefficient and pathology scores, increased levels of protective adhesion protein VE-cadherin and tight junction protein claudin-5, and decreased cytoplasmic p-FOX-O1 and nuclear β-catenin and FOX-O1 levels. Arch Pharm Res. 2023 Jun;46(6):564-572
Sprague-Dawley rats Oral administration model Oral gavage 30 mg/kg Paritaprevir and 20 mg/kg Ritonavir Once daily for 4 or 5 days To assess the impact of different liver sampling techniques on liver concentrations of Paritaprevir and Ritonavir. Results showed that drug concentrations in liver tissue were higher than in plasma, with the highest concentrations observed in surgically resected samples. Antimicrob Agents Chemother. 2017 Apr 24;61(5):e02283-16

Protocol

Bio Calculators
Preparing Stock Solutions 1mg 5mg 10mg

1 mM

5 mM

10 mM

1.31mL

0.26mL

0.13mL

6.53mL

1.31mL

0.65mL

13.06mL

2.61mL

1.31mL

References

 

Historical Records

Categories